THER (Theralink Technologies) Cyclically Adjusted Book per Share: $-246.51 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Theralink Technologies Cyclically Adjusted Book per Share?

Theralink Technologies THER -99.00% Cyclically Adjusted Book per Share is $-246.51 as of Dec. 2023.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theralink Technologies's adjusted book value per share for the three months ended in Dec. 2023 was $-0.009. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-246.51 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-04), Theralink Technologies's current stock price is $0.0001. Theralink Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $-246.51. Theralink Technologies's Cyclically Adjusted PB Ratio of today is .


Theralink Technologies  (OTCPK:THER) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theralink Technologies Cyclically Adjusted Book per Share Related Terms


Theralink Technologies Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Theralink Technologies's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralink Technologies Cyclically Adjusted Book per Share Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.06 0.00 -133.53 -222.01 -261.25

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -257.80 -265.71 -267.44 -261.25 -246.51

THER vs AXIM, ISCO, RMTG: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Theralink Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Cyclically Adjusted PB Ratio falls into.



Theralink Technologies Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theralink Technologies's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.009/306.7460*306.7460
=-0.009

Current CPI (Dec. 2023) = 306.7460.

Theralink Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201402 -621.000 234.781 -811.349
201405 -714.000 237.900 -920.625
201408 -713.000 237.852 -919.521
201411 -1,060.000 236.151 -1,376.876
201502 -1,044.000 234.722 -1,364.349
201505 -6.750 237.805 -8.707
201508 -1.667 238.316 -2.146
201512 7.303 236.525 9.471
201603 2.316 238.132 2.983
201606 -4.364 241.018 -5.554
201609 -4.544 241.428 -5.773
201612 -10.210 241.432 -12.972
201703 10.714 243.801 13.480
201706 11.462 244.955 14.353
201709 -18.216 246.819 -22.639
201712 -65.242 246.524 -81.180
201803 -17.838 249.554 -21.926
201806 -31.728 251.989 -38.622
201809 -30.398 252.439 -36.937
201812 -22.870 251.233 -27.923
201903 -29.685 254.202 -35.821
201906 -30.495 256.143 -36.520
201909 -28.553 256.759 -34.112
201912 -19.086 256.974 -22.783
202003 -22.682 258.115 -26.955
202006 0.747 257.797 0.889
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 -0.001 264.877 -0.001
202106 -0.001 271.696 -0.001
202109 -0.001 274.310 -0.001
202112 -0.001 278.802 -0.001
202203 -0.001 287.504 -0.001
202206 -0.001 296.311 -0.001
202209 -0.001 296.808 -0.001
202212 -0.007 296.797 -0.007
202303 -0.009 301.836 -0.009
202306 -0.008 305.109 -0.008
202309 -0.006 307.789 -0.006
202312 -0.009 306.746 -0.009

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-246.51 mean?
Theralink Technologies (THER) has a Cyclically Adjusted Book per Share of $-246.51 as of Dec. 2023. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theralink Technologies and its competitors.
Is Theralink Technologies' Cyclically Adjusted Book per Share too high?
Theralink Technologies' current Cyclically Adjusted Book per Share is $-246.51.
How does Theralink Technologies' Cyclically Adjusted Book per Share compare to AXIM and ISCO?
Theralink Technologies' Cyclically Adjusted Book per Share of $-246.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theralink Technologies and its competitors. Theralink Technologies's current Cyclically Adjusted Book per Share is $-246.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralink Technologies stock overvalued right now?
Theralink Technologies (THER) has a current Cyclically Adjusted Book per Share of $-246.51. The current Cyclically Adjusted Book per Share is $-246.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Theralink Technologies (THER), the current Cyclically Adjusted Book per Share is $-246.51 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theralink Technologies Business Description

Address 15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.